![Campbell Murray](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Campbell Murray
Directeur/Bestuurslid bij
LUMOS PHARMA, INC.
Profiel
Campbell Murray is the founder of Double Point Ventures LLC, founded in 2023, serving as Senior Advisor.
Current jobs include Executive Director at Lumos Pharma, Inc., Director at BioRelix, Inc., Director at Neurovance, Inc., and Director at Synchron, Inc. (starting 2025).
Former jobs include Chairman at Euthymics Bioscience, Inc., Director at Alios BioPharma, Inc., Rein Therapeutics, Inc., Annexon, Inc., Aerpio Therapeutics LLC, ProCertus BioPharm, Inc., Bionano Genomics, Inc., ImaginAb, Inc., Lemonaid Health, Inc., Expansion Therapeutics, Inc., TScan Therapeutics, Inc., Renovacor Holdings, Inc., and Akebia Therapeutics, Inc. Independent Director at Galera Therapeutics, Inc. (2012–2019) and Tokai Pharmaceuticals, Inc. (2014).
Director-Special Projects at Novartis Institutes for Biomedical Research, Inc. (2004–2005).
Managing Director at Novartis Services, Inc. and Novartis Venture Fund.
Managing Director at Novartis Venture Funds (USA) (2006–2020).
Partner at Agent Capital LLC (2023–2024).
Education includes an MBA from Harvard Business School and graduate studies at Harvard Kennedy School of Government.
Actieve functies van Campbell Murray
| Bedrijven | Functie | Begin |
|---|---|---|
| LUMOS PHARMA, INC. | Directeur/Bestuurslid | - |
Neurovance, Inc.
 Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that develops treatments for central nervous system disorders | Directeur/Bestuurslid | - |
BioRelix, Inc.
 BioRelix, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of antibiotics | Directeur/Bestuurslid | - |
Synchron, Inc.
 Synchron, Inc. Packaged SoftwareTechnology Services Operates as a neurotechnology company that develops endovascular brain-computer interface | Directeur/Bestuurslid | 01-10-2025 |
Eerdere bekende functies van Campbell Murray
| Bedrijven | Functie | Einde |
|---|---|---|
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments. | Private Equity Investor | 31-05-2024 |
Novartis Venture Funds (USA)
 Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Private Equity Investor | 01-09-2020 |
| GALERA T COM USD0. | Directeur/Bestuurslid | 06-11-2019 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases | Directeur/Bestuurslid | 16-10-2014 |
Novartis Institutes for Biomedical Research, Inc.
 Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Corporate Officer/Principal | 01-07-2005 |
Opleiding van Campbell Murray
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
59
Eerstegraads connecties
26
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 26 |
|---|---|
BioRelix, Inc.
BioRelix, Inc. Pharmaceuticals: MajorHealth Technology Engages in the development of antibiotics | Health Technology |
Alios BioPharma, Inc.
 Alios BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company which develops novel antiviral therapies for the treatment of respiratory diseases | Health Technology |
Rein Therapeutics, Inc.
 Rein Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops stapled peptide drugs | Health Technology |
Annexon, Inc.
 Annexon, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapeutics for neurodegenerative and autoimmune disorders | Health Technology |
Aerpio Therapeutics LLC
 Aerpio Therapeutics LLC Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company focused on advancing innovative therapies for vascular diseases | Health Technology |
Neurovance, Inc.
Neurovance, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biopharmaceutical company that develops treatments for central nervous system disorders | Commercial Services |
Galera Therapeutics, Inc.
 Galera Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs to reduce normal tissue toxicity from radiotherapy | Health Technology |
Novartis Venture Funds
 Novartis Venture Funds Investment ManagersFinance NVF invests in companies located across North America and Europe. The firm focuses on biotechnology & biopharmaceutical and Life science sectors. It provides financing for early and later stage transactions with an investment size up to USD 30 million per company and also acts as lead or co-lead investor. The firm takes a seat on the board of directors. | Finance |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops novel proprietary therapies for the treatment of prostate cancer and other hormonally driven diseases | Health Technology |
ProCertus BioPharm, Inc.
 ProCertus BioPharm, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-based pharmaceutical company | Health Technology |
Novartis Institutes for Biomedical Research, Inc.
Novartis Institutes for Biomedical Research, Inc. Miscellaneous Commercial ServicesCommercial Services Conducts biomedical researches | Commercial Services |
Akebia Therapeutics, Inc.
 Akebia Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for kidney diseases | Health Technology |
Bionano Genomics, Inc.
 Bionano Genomics, Inc. BiotechnologyHealth Technology Develops technologies for analysis of large biological molecules | Health Technology |
Novartis Services, Inc.
 Novartis Services, Inc. Pharmaceuticals: MajorHealth Technology Operates as pharmaceutical company | Health Technology |
Euthymics Bioscience, Inc.
 Euthymics Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Develops a novel medicine for alcohol use disorder (AUD) and smoking cessation | Commercial Services |
Novartis Venture Funds (USA)
Novartis Venture Funds (USA) Investment ManagersFinance Novartis Venture Funds (USA) focuses on investments in early-stage opportunities in the following areas: (1) new therapeutics and platforms (2) medical devices and implants (3) diagnostics and biomarkers and (4) drug delivery and biopolymers. The firm looks for opportunities that address unmet medical needs, result in significant clinical impact, are based on novel proprietary science and are capital efficient. They prefer to make initial investments at the early stage. Their objective is to grow their portfolio companies and follow with additional investments as the company progresses. Novartis prefers to make total investments of $15 million to 420 million over the life of a company, but they may make investments of as little as $100,000 in start-up companies. The firm leads or co-leads their deals and remains open to participating in larger syndicates. Novartis invests in opportunities in the US, Canada, Europe, Switzerland and the Asia/Pacific region. The firm takes an active role in supporting through board or observer representation on their portfolio companies' boards of directors | Finance |
ImaginAb, Inc.
 ImaginAb, Inc. Medical SpecialtiesHealth Technology Develops radiopharmaceutical and imaging agent products | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Kennedy School of Government
 Harvard Kennedy School of Government Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Icebreaker Health, Inc.
 Icebreaker Health, Inc. Medical/Nursing ServicesHealth Services Provides telehealth services | Health Services |
Synchron, Inc.
Synchron, Inc. Packaged SoftwareTechnology Services Operates as a neurotechnology company that develops endovascular brain-computer interface | Technology Services |
Expansion Therapeutics, Inc.
 Expansion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as drug discovery and development company for RNA-mediated diseases | Health Technology |
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments. | Finance |
TScan Therapeutics, Inc.
 TScan Therapeutics, Inc. BiotechnologyHealth Technology Develops T-cell therapies for cancer patients | Health Technology |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Develops transformative gene therapy | Health Technology |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
